Gensight Biologics SA
PAR:SIGHT

Watchlist Manager
Gensight Biologics SA Logo
Gensight Biologics SA
PAR:SIGHT
Watchlist
Price: 0.244 EUR -2.4% Market Closed
Market Cap: 30.4m EUR

Intrinsic Value

SIGHT's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

The intrinsic value of one SIGHT stock under the Base Case scenario is 0.238 EUR. Compared to the current market price of 0.244 EUR, Gensight Biologics SA is Overvalued by 2%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

SIGHT Intrinsic Value
0.238 EUR
Overvaluation 2%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation History
Gensight Biologics SA

Intrinsic Value History
Dive into the past to invest in the future

Uncover deeper insights with the Valuation History. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start now and learn if your stock is truly undervalued or overvalued!

Start Valuation
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
SIGHT
Valuation History
HIDDEN
Show
Valuation History Unavailable

Historical valuation for SIGHT cannot be conducted due to limitations such as insufficient data or other constraints.

Valuation In Progress...
Valuation In Progress...
0%

Fundamental Analysis

Gensight Biologics SA
PAR:SIGHT
FR
Biotechnology
Market Cap
30.4m EUR
IPO
Jul 13, 2016
FR
Biotechnology
Market Cap
30.4m EUR
IPO
Jul 13, 2016
Price
€false
EPS
€false
Company Overview
Loading...
Management
Loading...
Contacts
Loading...
How do you feel about SIGHT?
Bearish
Neutral
Bullish
AI Assistant
AI Assistant
Ask me anything about Gensight Biologics SA
Financials
Annual
Quarterly
TTM

Balance Sheet Decomposition
Gensight Biologics SA

Current Assets 13m
Cash & Short-Term Investments 6.9m
Receivables 1.3m
Other Current Assets 4.7m
Non-Current Assets 2m
Long-Term Investments 519k
PP&E 1.4m
Intangibles 66k
Efficiency

Free Cash Flow Analysis
Gensight Biologics SA

Last Value
3-Years Average
FCF Margin
Conversion Rate

Earnings Waterfall
Gensight Biologics SA

Revenue
2.4m EUR
Operating Expenses
-39.5m EUR
Operating Income
-37.1m EUR
Other Expenses
5m EUR
Net Income
-32.1m EUR
Fundamental Scores

SIGHT Profitability Score
Profitability Due Diligence

Gensight Biologics SA's profitability score is 26/100. The higher the profitability score, the more profitable the company is.

26/100
Profitability
Score

Gensight Biologics SA's profitability score is 26/100. The higher the profitability score, the more profitable the company is.

SIGHT Solvency Score
Solvency Due Diligence

Gensight Biologics SA's solvency score is 28/100. The higher the solvency score, the more solvent the company is.

Low D/E
Positive Net Debt
Short-Term Solvency
Long-Term Solvency
28/100
Solvency
Score

Gensight Biologics SA's solvency score is 28/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

SIGHT Price Targets Summary
Gensight Biologics SA

Wall Street analysts forecast SIGHT stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for SIGHT is 0.388 EUR with a low forecast of 0.364 EUR and a high forecast of 0.42 EUR.

Lowest
Price Target
0.364 EUR
49% Upside
Average
Price Target
0.388 EUR
59% Upside
Highest
Price Target
0.42 EUR
72% Upside
View Analyst Estimates
View Analyst Estimates

Dividends

Gensight Biologics SA
does not pay dividends
Shareholder Yield

Current shareholder yield for SIGHT is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Ownership

SIGHT Insider Trading
Buy and sell transactions by insiders

What is the Intrinsic Value of one SIGHT stock?

The intrinsic value of one SIGHT stock under the Base Case scenario is 0.238 EUR.

Is SIGHT stock undervalued or overvalued?

Compared to the current market price of 0.244 EUR, Gensight Biologics SA is Overvalued by 2%.

Back to Top